Traditional Indian medicine was long criticised for its inability to showcase proper scientific validation of drugs developed under Ayush. Though Ayurveda, Unani and Siddha are extremely popular among Indians, the traditional medicine systems struggled against Allopathy which is backed by scientific evidence.
But, this could be a thing of the past with the country’s premier institute, Centre for Cellular and Molecular Biology (CCMB), deciding to makes it foray into research and documentation of plant-based medicines in India.
CCMB has now entered into a MoU with Ghaziabad-based Indian Pharmacopeia Commission (IPC) to take up documentation, validation and characterisation of Indian herbal drugs. “Scientific validation and characterisation of herbal drugs will not only help authentication of such drugs but, also bring credibility to the industry and solidify the traditional Indian knowledge of thousands of years,” CCMB Director Dr RK Mishra said.
The research on plant-based drugs by CCMB and IPC could provide much-needed scientific and data-based evidence on plant-based drugs, especially for Ayush. The study on herbal medicines will be based on modern scientific methods, which will facilitate in regulatory process and also boost the Indian medicine sector.
On Saturday, the agreement was signed by Dr Mishra and Secretary-cum-Scientific Director, IPC, Dr GN Singh. “The MoU will come into immediate effect and is important in the current scenario because of the increase in use of herbal medicine in India,” Dr Singh said.
As part of the collaboration, CCMB and IPC will work towards the documentation and identification of herbal drugs based on DNA barcode analysis. Researchers pointed out that the collaboration on Indian herbal drugs and plant-based pharmaceuticals will lead to significant usage and export of traditional Indian medicine.
Both the research institutions will also work on biosimilars, which are medical products that are almost an identical copy of an original product manufactured by a company. According to a 2017 report of CII, the biosimiliar market in India was Rs 15,000 crore and is expected to cross Rs 250,000 crore by 2030. – Telangana Today